한국미생물·생명공학회지 (Microbiology and Biotechnology Letters)

  • 제24권5호
  • /
  • Pages.574-578
  • /
  • 1996
  • /
  • 1598-642X(pISSN)
  • /
  • 2234-7305(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지

Aspergillus candidusF1484 균주가 생산하는 항진균 화합물의 분리 및 특성

  • 김성욱 (한국과학기술연구원 생명공학연구소) ;
  • 이소영 (한국과학기술연구원 생명공학연구소) ;
  • 김성규 (한국과학기술연구원 생명공학연구소) ;
  • 손광희 (한국과학기술연구원 생명공학연구소) ;
  • 김영국 (한국과학기술연구원 생명공학연구소) ;
  • 문석식 (공주대학교 화학과) ;
  • 복성해 (한국과학기술연구원 생명공학연구소)
  • 발행 : 1996.10.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In the course of screening for the antifungal compounds against Candida albicans, an antifungal compound (F1480) was isolated from the culture broth of Aspergillus candidus F1484. Isolation and purification of compound F1484 were performed using ethyl acetate extraction, silica gel column chromatography, ODS column chromatography, and preparative HPLC. The structure of compound F1484 was determined by the spectroscopic analyses of EI-MS, $^{13}$C, $^{1}$H-NMR, DEPT, HMQC, and HMBC. This compound appeared to have a structure of antifungal agent, chloroflavonin. In addition to antifungal activities against the yeast phase of Candida species, compound F1484 showed cytotoxic effect against various human tumor cell lines.

키워드

참고문헌

  1. Antifungal Drug Therapy Treatment of fungal infections in the human immunodeficiency virus-infected individual. Greene S.I;P.H Jocobs(eds.);L.Nall(eds.)
  2. 抗生物質 硏究の 最先端, 抗眞菌抗生物質の screening. 田中日靑雄;大野雅三と大村智(eds.)
  3. Rev. Infec. Dis. v.11 Problems in management of opportunistic fungal infections. Amstrong D.
  4. Science v.266 The emerging fungal threat. Sternberg S.
  5. Rev. Inf. Dis v.11 New spectrum of fungal infections in patients with cancer. Anaissie E;G.P.Bodey;H.Kantarjian;J.Ro;S.E.Vartivarian;R.Hepfer;J.Hoy;K.Rolston.
  6. Science v.264 Human Mycoses : Drugs and targets for emerging pathogens. Georgopapadakou N.H;T.J.Walsh.
  7. New approaches for antifungal drugs. The need for new antifungal drugs. Clark A.M.
  8. Antifungal agents. The search for bioactive compounds from microorganisms. Tanaka Y;S.Omura(ed.)
  9. Emerging targets in antibacterial and antifungal chemotherapy. Invasive fungal infections: Problems and challenges for developing new antifungal compounds. Walsh T.J;J.Sutcliffe(eds.);N.H.Georgopapadakou(eds.)
  10. J. Pediatr v.50 Laboratory and clinical studies on candidiasis in the newborn infant. Tasohdjlan C.L;P.J.Kozina.
  11. Kor. J.Appl. Microbiol. Biotechnol. v.23 Screenign of antifungal compounds from microorganisms with preferential activity against the mycelial phase of Candida albicans. Kim.S.U;J.Y.Nam;B.M.Kwon;K.H.Son;S.H.Bok.
  12. Mycologia v.59 Survival of fungus cultures maintained under mineral oil for twelve years. Little G.N;M.A.Gordon.
  13. J. Ind. Microbiol v.8 A novel antifungal from an Actinomadurae with preferential activity against the mycelial phase of Candida albicans. Gullo V;I.Gunnarsson;V.Hegde;A.Horan;D.Leoberiberg;J.Marquez;M.Patel;M.Puar;J.Schwartz
  14. Antibiotics in laboratory medicine. Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. Mcginnis M.R;M.G.Rinaldi;V.Lorian(ed.)
  15. J. Natl. Cancer Inst. v.82 New colorimetric cytotoxicity assay for anticancer-drug screening. Skehan P;R.Streng;D.Scudiero;A.Monks;J.Mcmahon;D.Vistica;J.T.Warren;H.Bokesch;S.Kenney;M.R.Boyd.
  16. Arch. Pharm. Res. v.15 Anticancer activity of Psoralea corylifolia. Ryu S.Y;S.W.Choi;C.O.Lee;O.P.Zee.
  17. J.Chem. Soc. v.C Structure of Chloroflavonin. Bird A.E;A.C.Marshall.
  18. J. Chem. Soc. Chem. Comm. Biosynthesis of chloroflavonin in Aspergillus candidus: A novel fungal route to flavonoids. Burns M.K;J.M.Coffin;I.Kurobane;L.C.Vining.